Patient Perspectives:

THE 2024 **IBS IMPACT** REPORT

Salix Pharmaceuticals, in partnership with Fairleigh Dickinson University, has surveyed over 850 Irritable Bowel Syndrome (IBS) or Chronic Idiopathic Constipation (CIC) patients in the United States to better understand their experience.

~8 out of **10**
think their healthcare provider (HCP) makes them feel comfortable discussing their symptoms, however, **88% typically focus on talking about their primary symptom**

94%
find it helpful when HCPs post educational information to social media and **the vast majority (92%) say the content aligns with their understanding of IBS**

7 out of 10 surveyed stated that their IBS symptoms at least sometimes cause them to skip events

Around **80%** believe their HCP makes the best treatment choice for them

~1 out of 5 believe they do not

Data is from a non-probability online sample of U.S. residents and was carried out in January 2024 by Fairleigh Dickinson University's FDU Poll. Participants were recruited based on previously reported gastrointestinal issues. The overall sample size of the survey was 852 respondents (IBS-D: n=436; IBS-C/CIC: n=416) and was screened to include only those who self-reported having IBS with constipation, chronic idiopathic constipation or IBS with diarrhea. Respondents were drawn from multiple panels of U.S. residents and were compensated for their time (maximum $4.00). Due to the limitations of this survey, results may not be representative of the general IBS or CIC population.
IBS.0016.USA.24

Salix Pharmaceuticals

IBS-C/CIC

TOP 5 symptoms that made respondents seek treatment:

Constipation I Abdominal discomfort
Stomach pain I Hard to pass bowel movements
Bloating

Respondents were most embarrassed to discuss **constipation** and **hard to pass bowel movements** with their healthcare provider (HCP)

96% Close to all respondents want HCPs to ask about all their symptoms rather than just primary one

Almost **7 out of 10** respondents take/ have taken a prescription treatment

...But **67%** of these stated that their Rx has met only some of their treatment goals

Top 3 unresolved symptoms

- **44%** Stomach pain
- **42%** Abdominal discomfort
- **38%** Bloating

9 out of 10 respondents are willing to switch to a different Rx if it meets their treatment goals

IBS-D

Nearly **9 in 10** at least sometimes need to plan for their symptoms when they leave home

TOP 2 symptoms that made respondents seek treatment:

Diarrhea
Stomach pain

86% IBS-D respondents want HCPs to ask about additional symptoms

65% IBS-D patients report that they view diarrhea as their **most embarrassing** symptom to discuss with their HCP, followed by urgency to have a bowel movement (61%)

Roughly 3 in 4 report their prescription treatment wasn't meeting all treatment goals

94% IBS-D respondents wanted their HCPs to ask about their symptom management goals

84% of those reporting unresolved diarrhea and/or stomach pain are willing to try different medication

89% are interested in shorter duration of treatment with longer period of relief

More than half of surveyed IBS patients reported they felt alone in their IBS experience. **Let's work together** and be the difference for these patients.

Data is from a non-probability online sample of U.S. residents and was carried out in January 2024 by Fairleigh Dickinson University's FDU Poll. Participants were recruited based on previously reported gastrointestinal issues. The overall sample size of the survey was 852 respondents (IBS-D: n=436; IBS-C/CIC: n=416) and was screened to include only those who self-reported having IBS with constipation, chronic idiopathic constipation or IBS with diarrhea. Respondents were drawn from multiple panels of U.S. residents and were compensated for their time (maximum $4.00). Due to the limitations of this survey, results may not be representative of the general IBS or CIC population.
IBS.0016.USA.24

Salix Pharmaceuticals